GALECTIN THERAPEUTICS INC (GALT)
CIK 1133416 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 100.8M shares as of Aug 6, 2026 (10-Q). Share count fell from 77.1M to 15.6M between Nov 1, 2011 and Mar 29, 2012, a pattern consistent with a reverse split (roughly 1-for-5); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
~7 months of cash left
burning $6.0M / quarter
Full breakdown: cash runway tool · source filing →
Warrants
Warrants outstanding: 4.2M underlying shares, as reported Dec 31, 2025 (10-K).
Reported exercise price: $7 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $500,000 as of Sep 30, 2022.
Down-round (price protection) accounting has been tagged in this filer’s XBRL: some instrument carries repricing protection. Which tranche requires reading the exhibits.
Rough fully diluted estimate: 105.0M = 100.8M O/S + 4.2M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| April Convertible Promissory Note | $10.0M | — | $5 | 2% | ~2.0M sh |
| September Convertible Promissory Note | not tagged | — | $8.64 | 2% | — |
| December Convertible Promissory Note | not tagged | — | $5.43 | 2% | — |
If every note above converted at its tagged price: ~2.0M new shares on 100.8M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 14, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 100.8M | Aug 6, 2026 |
| + Warrants (aggregate, as tagged) (if exercised) | 4.2M | Dec 31, 2025 |
| + April Convertible Promissory Note (if fully converted) | 2.0M | Apr 16, 2021 |
| Fully diluted estimate | 107.0M | +6.1% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $200.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 1 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full GALT workspace